سعر سوفيناسين معلق 1 مجم/مل 2024

Sofenacin oral suspension containing solifenacin succinate 1 mg/ml (120 ml bottle) by Marcyrl, an antimuscarinic for overactive bladder.

• Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency in adults with overactive bladder syndrome.Population: Adultselectronic medicines compendium (emc), UK
• Neurogenic detrusor overactivity in paediatric patients aged 2 to 18 years.Population: Children and adolescents 2-18 yearselectronic medicines compendium (emc), UK

• Most common: dry mouth (11% at 5 mg, 22% at 10 mg); common: constipation, nausea, dyspepsia, abdominal pain, blurred vision. Children with NDO: constipation, dry mouth, abdominal pain, somnolence, urinary tract infection and QT prolongation.International label, same formulation · electronic medicines compendium (emc), UK

• Urinary retention (when used for overactive bladder); severe gastrointestinal condition including toxic megacolon; myasthenia gravis; narrow-angle glaucoma; hypersensitivity; haemodialysis; severe hepatic impairment; severe renal or moderate hepatic impairment together with a potent CYP3A4 inhibitor.International label, same formulation · electronic medicines compendium (emc), UK

• Use with caution in bladder outflow obstruction (without clean intermittent catheterisation), GI obstructive disorders or decreased GI motility, hiatus hernia/reflux, and autonomic neuropathy; QT prolongation and torsades de pointes reported in patients with risk factors.International label, same formulation · electronic medicines compendium (emc), UK
• Angioedema with airway obstruction and anaphylactic reactions have been reported; discontinue and treat appropriately.International label, same formulation · electronic medicines compendium (emc), UK
• Contains methyl and propyl parahydroxybenzoate (possible delayed allergic reactions), propylene glycol (20 mg/ml) and a small amount of ethanol (48.4 mg per 10 ml) in the UK product; Egyptian excipients not verified.International label, same formulation · electronic medicines compendium (emc), UK

• Potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, nelfinavir, itraconazole)Increase solifenacin exposure (2- to 3-fold AUC with ketoconazole); adults max 5 mg (5 ml), children no more than the starting dose.electronic medicines compendium (emc), UK
• Other anticholinergic medicinesMore pronounced therapeutic and undesirable effects; allow about one week after stopping solifenacin before starting another anticholinergic.electronic medicines compendium (emc), UK
• Prokinetics (metoclopramide, cisapride)Solifenacin can reduce their effect.electronic medicines compendium (emc), UK

• No clinical data in pregnancy; animal studies show no direct harmful effects on fertility, embryofetal development or parturition; potential human risk unknown, so prescribe with caution.International label, same formulation · electronic medicines compendium (emc), UK
• No data on excretion in human milk; in mice it was excreted in milk and caused dose-dependent failure to thrive in pups, so use should be avoided during breast-feeding.International label, same formulation · electronic medicines compendium (emc), UK

• Solifenacin succinate: Competitive muscarinic receptor antagonist; reduces detrusor (bladder smooth muscle) contraction.